Added to YB: 2025-01-07
Pitch date: 2025-01-05
GILD [bullish]
Gilead Sciences, Inc.
+35.49%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Market Cap
$150.4B
Pitch Price
$88.87
Price Target
115.00 (-4%)
Dividend
2.61%
EV/EBITDA
11.52
P/E
18.87
EV/Sales
5.66
Sector
Biotechnology
Category
growth
Gilead Sciences, Inc. - $GILD
GILD: Lencapavir HIV prevention drug awaiting FDA approval, $3-4B peak sales potential. Hepatitis portfolio still significant ($2B/yr). Seladalpar acquisition for PBC ($700M peak). Oncology progress slow but steady. Revenue growth guidance up to 4% for 2024. $115 fair value estimate. Management aims for 1/3 oncology revenue by 2030.
Read full article (3 min)